ABIVAX Société Anonyme (NASDAQ:ABVX) Now Covered by Analysts at Laidlaw

Laidlaw began coverage on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a research report released on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $48.00 price objective on the stock.

ABVX has been the topic of several other reports. Piper Sandler started coverage on ABIVAX Société Anonyme in a report on Monday, April 29th. They set an overweight rating and a $42.00 price objective on the stock. Morgan Stanley upped their price objective on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an equal weight rating in a report on Thursday, April 11th. BTIG Research began coverage on ABIVAX Société Anonyme in a report on Monday, May 20th. They set a buy rating and a $43.00 price objective on the stock. Finally, Guggenheim began coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They set a buy rating and a $50.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and a consensus target price of $36.50.

ABIVAX Société Anonyme Stock Down 0.4 %

Shares of ABVX opened at $11.76 on Monday. ABIVAX Société Anonyme has a 1 year low of $7.99 and a 1 year high of $17.02. The business’s 50 day simple moving average is $13.18 and its 200-day simple moving average is $13.61. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.23.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in ABIVAX Société Anonyme in the 1st quarter valued at $81,000. Capstone Investment Advisors LLC bought a new position in ABIVAX Société Anonyme in the 4th quarter valued at $618,000. Ghisallo Capital Management LLC bought a new position in ABIVAX Société Anonyme in the 4th quarter valued at $642,000. Kennedy Capital Management LLC grew its position in ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after acquiring an additional 31,331 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new position in ABIVAX Société Anonyme in the 1st quarter valued at $5,411,000. Institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.